AMGN Q3 FY2026 earnings call
Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, with 17 products growing double-digit. Non-GAAP operating margin was 47%, and free cash flow reached $3.7B. The company raised full-year 2026 guidance, expecting revenue of $38.9B-$39.7B and EPS of $22.90-$23.70. Key growth drivers include Repatha, EVENITY, TEZSPIRE, and UPLIZNA, with notable increases in rare disease and oncology portfolios.
How this was made
The 30-second read
Why it matters
The raised guidance and strong product growth are likely to lift the stock, while competitive and pricing risks remain.
Market read
First‑report earnings and guidance lift for a large‑cap biotech, offering a clear trading catalyst.
What to watch
Potential pricing pressure on biosimilars and upcoming regulatory filings could temper upside.
Background
Amgen's Q3 earnings call provided detailed financials, product performance, and pipeline updates.
Ticker impact
Amgen reported Q3 2026 results with revenue up 8% YoY and raised full-year guidance to $38.9‑$39.7B and EPS $22.90‑$23.70.
upward pressure as investors price in higher revenue and earnings expectations
The earnings beat and guidance lift are primary disclosures for a large‑cap biotech, providing a clear catalyst for buying.
Market effects
Biotech sector may see a rally on the back of Amgen's strong guidance, boosting peers with similar pipelines.
U.S. markets likely to open higher in biotech‑heavy indices.
Amgen's results could influence global pharma sentiment, especially in Europe and Asia where its products are sold.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback on profit‑taking.
Key entities
- companyAmgen
US‑listed biotech firm reporting Q3 2026 results.
- executiveBob Bradway
Amgen CEO commenting on guidance and strategy.
